Bound­less Bio seeks $88M in IPO as it runs two Ph1 can­cer tri­als

The spring IPO class is here.

Bound­less Bio, a can­cer biotech with two dif­fer­ent oral small mol­e­cules in Phase 1 test­ing, eyes about $88.4 mil­lion in net pro­ceeds from its pro­posed IPO.

The Nas­daq list­ing as $BOLD is like­ly to come in at a price range of $15 to $17 per share, Bound­less said in a Thurs­day morn­ing se­cu­ri­ties fil­ing, not­ing the mon­ey would take the com­pa­ny in­to the sec­ond half of 2026. At the end of last year, the start­up had $120 mil­lion in cash, equiv­a­lents and short-term in­vest­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER